Norway Savings Bank Acquires 941 Shares of IDEXX Laboratories, Inc. $IDXX

Norway Savings Bank boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 25.5% in the fourth quarter, HoldingsChannel reports. The firm owned 4,631 shares of the company’s stock after acquiring an additional 941 shares during the period. IDEXX Laboratories makes up 1.4% of Norway Savings Bank’s portfolio, making the stock its 21st biggest position. Norway Savings Bank’s holdings in IDEXX Laboratories were worth $3,133,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Empowered Funds LLC increased its stake in shares of IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after buying an additional 95 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in IDEXX Laboratories during the 2nd quarter worth about $265,000. TD Waterhouse Canada Inc. lifted its position in IDEXX Laboratories by 249.6% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 430 shares of the company’s stock worth $233,000 after buying an additional 307 shares in the last quarter. Swiss National Bank grew its holdings in IDEXX Laboratories by 6.2% during the 2nd quarter. Swiss National Bank now owns 245,300 shares of the company’s stock worth $131,564,000 after acquiring an additional 14,300 shares during the last quarter. Finally, DNB Asset Management AS grew its holdings in IDEXX Laboratories by 3.4% during the 2nd quarter. DNB Asset Management AS now owns 15,338 shares of the company’s stock worth $8,226,000 after acquiring an additional 511 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Piper Sandler dropped their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. BTIG Research decreased their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Barclays lowered their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. UBS Group dropped their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research report on Tuesday, February 3rd. Finally, Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $577.26 on Monday. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The stock has a market capitalization of $45.90 billion, a P/E ratio of 44.17, a P/E/G ratio of 3.50 and a beta of 1.66. The business has a 50-day moving average price of $645.73 and a two-hundred day moving average price of $664.71.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the business posted $2.53 EPS. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 2,693 shares of the company’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the completion of the sale, the executive vice president owned 19,899 shares in the company, valued at approximately $13,163,984.46. The trade was a 11.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total value of $15,338,011.30. Following the completion of the transaction, the chief executive officer directly owned 83,606 shares in the company, valued at approximately $54,975,125.30. This trade represents a 21.81% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 45,957 shares of company stock valued at $29,862,109. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.